Document is current
Any future updates will be listed below
-
Authors
Suthahar, Navin https://orcid.org/0000-0002-7781-2897
Gansevoort, Ron T.
Kok, Thomas F.
El-Qendouci, Maissa
Petersen, Teun B.
Bakker, Stephan J. L.
Boersma, Eric
Damman, Kevin
Kardys, Isabella
Rienstra, Michiel
de Boer, Rudolf A. https://orcid.org/0000-0002-4775-9140
-
Funding
Funding for this research was provided by:
Hartstichting (01-002-2022-0118 ; 848090001; CVON 2014–9 ; CVON 2017-11; CVON-AI 2018B017, 2017-21; 2017-11; 2018-30; 2020B005; 01-003-2022-0358)
Horizon 2020 Framework Programme (EHRA-PATHS 945260)
European Research Council (ERC CoG 818715)
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 4 July 2025
First Online: 12 August 2025
Competing interests
: Outside the current work, R.A.d.B. has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol-Myers Squibb, NovoNordisk, Roche and Zoll. R.A.d.B. received travel support from Abbott and NovoNordisk. The institution where R.A.d.B. is employed has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, Novo Nordisk and Roche. M.R. received consultancy fees from Bayer (OCEANIC-AF national PI), InCarda Therapeutics (RESTORE-SR national PI) to the institution. I.K. received travel reimbursement from Olink and SomaLogic. The remaining authors do not have anything to disclose.
